Seek Returns

ICLR vs. KYMR: ICON vs. Kymera Therapeutics Stock Comparison

How do ICON (ICLR) and Kymera Therapeutics (KYMR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

ICON (ICLR) and Kymera Therapeutics (KYMR) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ICLR is classified in Life Sciences Tools & Services while KYMR is classified in Biotechnology.

ICON (ICLR) has more than two decades of public-market history since May 15, 1998, whereas Kymera Therapeutics (KYMR) listed on August 21, 2020 and has a much shorter record to draw on.

Company profile comparison for ICON (ICLR) and Kymera Therapeutics (KYMR)
Profile ItemICLRKYMR
NameICON plcKymera Therapeutics Inc.
Country/RegionIrelandUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesBiotechnology
GICS Sub-IndustryLife Sciences Tools & ServicesBiotechnology
Market Capitalization15.34 billion USD11.25 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateMay 15, 1998August 21, 2020
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

ICLR
KYMR
GSPC
Loading price history…
ICON (ICLR) vs. Kymera Therapeutics (KYMR), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for ICON (ICLR) and Kymera Therapeutics (KYMR). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for ICON (ICLR) and Kymera Therapeutics (KYMR). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for ICON (ICLR) and Kymera Therapeutics (KYMR)
MetricICLRKYMR
Total Return (1Y)30.55%131.52%
Total Return (3Y, Annualized)-6.05%111.65%
Total Return (5Y, Annualized)-5.40%15.68%

Risk Profile

Drawdown History

ICLR
KYMR
GSPC
Loading price history…
ICON (ICLR) vs. Kymera Therapeutics (KYMR), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for ICON (ICLR) and Kymera Therapeutics (KYMR). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for ICON (ICLR) and Kymera Therapeutics (KYMR)
MetricICLRKYMR
Volatility (1Y, Annualized)68.62%62.83%
Beta (5Y)1.172.00
Max Drawdown (5Y)-76.87%-83.27%
Avg. Volume (3M)943.50K833.05K

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ICLR and KYMR are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for ICON (ICLR) and Kymera Therapeutics (KYMR)
MetricICLRKYMR
Sharpe Ratio (1Y)0.382.03
Sortino Ratio (1Y)0.524.16

Profitability

ROE (TTM)

Kymera Therapeutics (KYMR) reports a negative ROE of -27.29%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile ICON (ICLR) reports 4.70%, ranking against industry peers normally.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.70%

Max
109.18%
Q3
6.23%
ICLR
4.70%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

-27.29%

Max
109.18%
Q3
6.23%
Median
-26.66%
KYMR
-27.29%
Q1
-64.05%
Min
-167.77%
Loading chart…
ICON (ICLR) vs. Kymera Therapeutics (KYMR): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

ICON (ICLR) at 5.26% retains a top-quartile share of revenue as profit, ahead of Kymera Therapeutics (KYMR) at 0.00%, which keeps about the industry-typical share.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.26%

Max
18.05%
ICLR
5.26%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
KYMR
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
ICON (ICLR) vs. Kymera Therapeutics (KYMR): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Kymera Therapeutics (KYMR) reports a negative operating margin of -396.04%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile ICON (ICLR) reports 10.73%, ranking against industry peers normally.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.73%

Max
83.12%
Q3
14.77%
ICLR
10.73%
Median
0.00%
Q1
-78.82%
Min
-207.40%

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

-396.04%

Max
83.12%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
KYMR
-396.04%
Loading chart…
ICON (ICLR) vs. Kymera Therapeutics (KYMR): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for ICON (ICLR) and Kymera Therapeutics (KYMR)
MetricICLRKYMR
ROE (TTM)4.70%-27.29%
ROA (TTM)0.85%-17.64%
Net Margin (TTM)5.26%0.00%
Operating Margin (TTM)10.73%-396.04%
Gross Margin (TTM)23.44%0.00%

Growth

Revenue Growth

ICON (ICLR) at 0.76% is around its peer norm for revenue growth, while Kymera Therapeutics (KYMR) at -16.70% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Loading chart…
ICON (ICLR) vs. Kymera Therapeutics (KYMR): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: ICON (ICLR) reports EPS growth of -71.56%, ranked against its industry; Kymera Therapeutics (KYMR) has no EPS growth figure this period.

Loading chart…
ICON (ICLR) vs. Kymera Therapeutics (KYMR): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for ICON (ICLR) and Kymera Therapeutics (KYMR)
MetricICLRKYMR
Revenue Growth (YoY)0.76%-16.70%
Revenue Growth (3Y CAGR)2.15%-5.74%
EPS Growth (YoY)-71.56%--
EPS Growth (3Y CAGR)-23.82%--

Financial Strength

Current Ratio (MRQ)

Kymera Therapeutics (KYMR) at 11.13 keeps current ratio within its industry’s typical mid-range, while ICON (ICLR) at 1.32 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ICLR.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.32

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
ICLR
1.32
Min
0.10

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

11.13

Max
25.13
Q3
12.13
KYMR
11.13
Median
5.52
Q1
2.47
Min
0.10
Loading chart…
ICON (ICLR) vs. Kymera Therapeutics (KYMR): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both ICON (ICLR) at 0.38 and Kymera Therapeutics (KYMR) at 0.05 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.38

Max
1.42
Q3
0.65
ICLR
0.38
Median
0.15
Q1
0.02
Min
0.00

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.05

Max
1.42
Q3
0.65
Median
0.15
KYMR
0.05
Q1
0.02
Min
0.00
Loading chart…
ICON (ICLR) vs. Kymera Therapeutics (KYMR): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for ICON (ICLR) and Kymera Therapeutics (KYMR)
MetricICLRKYMR
Current Ratio (MRQ)1.3211.13
Debt / Equity (MRQ)0.380.05
Net Debt / EBITDA5.55--

Dividends

Dividend Yield (TTM)

Neither ICON (ICLR) nor Kymera Therapeutics (KYMR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ICLR
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

KYMR
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
ICON (ICLR) vs. Kymera Therapeutics (KYMR): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither ICON (ICLR) nor Kymera Therapeutics (KYMR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ICLR
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

KYMR
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
ICON (ICLR) vs. Kymera Therapeutics (KYMR): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for ICON (ICLR) and Kymera Therapeutics (KYMR)
MetricICLRKYMR
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: ICON (ICLR) trades at 81.90 times trailing earnings, ranked against its peers, while Kymera Therapeutics (KYMR) has no P/E ratio this period.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

81.90

Max
85.34
ICLR
81.90
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
KYMR
--
Loading chart…
ICON (ICLR) vs. Kymera Therapeutics (KYMR): KYMR does not report P/E ratio, so it has no value marker; ICLR is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

ICON (ICLR) at 1.86 sits in the cheaper P/S ratio quartile while Kymera Therapeutics (KYMR) at 110.00 prices above its industry range — a wide gap in sales valuation between them.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.86

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
ICLR
1.86
Min
0.01

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

110.00

KYMR
110.00
Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
ICON (ICLR) vs. Kymera Therapeutics (KYMR): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

ICON (ICLR) at 1.68 looks cheap against book in the lower P/B ratio quartile, while Kymera Therapeutics (KYMR) at 6.96 carries a premium in the upper quartile — a clear price-to-book gap.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.68

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
ICLR
1.68
Min
-5.59

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.96

Max
13.53
KYMR
6.96
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
ICON (ICLR) vs. Kymera Therapeutics (KYMR): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for ICON (ICLR) and Kymera Therapeutics (KYMR)
MetricICLRKYMR
P/E Ratio (TTM)81.90--
P/S Ratio (TTM)1.86110.00
P/B Ratio (MRQ)1.686.96
Free Cash Flow Yield (TTM)3.51%-1.46%